High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Lung Cancer

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2016.09.009PMID 27794409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

  2016cited by this paper
• Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer

  2015cited by this paper
• Semi-synthesis of a HGF/SF kringle one (K1) domain scaffold generates a potent in vivo MET receptor agonist

  2015cited by this paper
• Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

  2015cited by this paper
• Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

  2015cited by this paper
• Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

  2015cited by this paper
• Necrosis- and apoptosis-related Met cleavages have divergent functional consequences

  2015cited by this paper
• Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

  2015cited by this paper
• Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma

  2014cited by this paper
• Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

  2014cited by this paper
• Thirty years of research on met receptor to move a biomarker from bench to bedside.

  2014cited by this paper
• Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

  2014cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer

  2013cited by this paper
• Hepatocyte Growth Factor, a Determinant of Airspace Homeostasis in the Murine Lung

  2013cited by this paper
• Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity

  2013cited by this paper
• Met degradation: more than one stone to shoot a receptor down

  2012cited by this paper
• HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.

  2012cited by this paper
• Shedding‐Generated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway

  2012cited by this paper
• cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

  2012cited by this paper
• Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer

  2012cited by this paper
• c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas

  2012cited by this paper
• MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

  2011cited by this paper
• Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

  2011cited by this paper
• Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status

  2010cited by this paper
• Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status

  2010cited by this paper
• Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

  2009cited by this paper
• Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis

  2007cited by this paper
• c-Met Ectodomain Shedding Rate Correlates with Malignant Potential

  2006cited by this paper
• Met, metastasis, motility and more

  2003cited by this paper
• Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway

  2002cited by this paper
• Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway

  2002cited by this paper
• Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons.

  1997cited by this paper
• Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

  1997cited by this paper
• Scatter factor/hepatocyte growth factor is essential for liver development

  1995cited by this paper
• Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

  1995cited by this paper
• Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

  1995cited by this paper
• A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.

  1994cited by this paper
• Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

  1994cited by this paper

• A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

  2025cites this paper
• The Occurrence of MET Ectodomain Shedding in Oral Cancer and Its Potential Impact on the Use of Targeted Therapies

  2022cites this paper
• Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

  2022cites this paper
• The role of MET in chemotherapy resistance

  2021cites this paper
• A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

  2019cites this paper
• Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase

  2019cites this paper
• Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding

  2019cites this paper
• Untying the gordion knot of targeting MET in cancer.

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• [MET receptor inhibition: Hope against resistance to targeted therapies?]

  2016cites this paper